Formerly known as EG427, the gene therapy specialist closed a €33 million (about $37.7 million) Series C to advance its lead program in chronic neuro-urology indications. The funding comes as the company rebrands to reflect renewed momentum in clinical development. The company’s lead program targets an area where durable functional outcomes and delivery safety are central for regulators and payers, and Series C capital typically supports dose-ranging refinements, trial expansion planning, and continued manufacturing readiness. With this round, the biotech is positioning for near-term milestones tied to clinical readouts and next-step protocol execution.